Diversify Wealth Management LLC Purchases 14,626 Shares of Abivax SA Sponsored ADR $ABVX

Diversify Wealth Management LLC increased its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 470.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 17,736 shares of the company’s stock after acquiring an additional 14,626 shares during the quarter. Diversify Wealth Management LLC’s holdings in Abivax were worth $1,884,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Candriam S.C.A. acquired a new position in Abivax in the first quarter valued at about $4,015,000. Hsbc Holdings PLC increased its holdings in shares of Abivax by 335.9% in the first quarter. Hsbc Holdings PLC now owns 15,426 shares of the company’s stock worth $1,712,000 after acquiring an additional 11,887 shares in the last quarter. Personal CFO Solutions LLC raised its position in shares of Abivax by 10.5% during the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock worth $337,000 after purchasing an additional 288 shares during the period. AdvisorShares Investments LLC raised its position in shares of Abivax by 5.4% during the first quarter. AdvisorShares Investments LLC now owns 11,802 shares of the company’s stock worth $1,314,000 after purchasing an additional 602 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Abivax during the 1st quarter valued at about $638,000. 47.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Leerink Partners boosted their price objective on Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Wall Street Zen upgraded shares of Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and lifted their price target for the company from $108.00 to $158.00 in a research note on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Finally, Wedbush upped their price target on shares of Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a report on Tuesday, June 30th. Fourteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $148.54.

Abivax Price Performance

Shares of Abivax stock opened at $134.91 on Wednesday. The firm has a market cap of $10.76 billion, a price-to-earnings ratio of -25.89 and a beta of 0.87. The stock’s 50-day moving average is $116.22 and its 200-day moving average is $118.45. Abivax SA Sponsored ADR has a one year low of $8.85 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.